Europe Cardiac Assist Devices Market Report

Europe Cardiac Assist Devices Market Size

The europe cardiac assist devices market Size was valued at USD 649.72 million in 2025, is expected to have 8.72% CAGR from 2026 to 2034, and be worth USD 1378.83 million by 2034 from USD 706.38 million in 2026.

Cardiac assist devices are mechanical pumps and electronic implants designed to support a weakened heart's ability to circulate blood or maintain a steady rhythm. These life-sustaining technologies serve as a bridge to recovery, a bridge to transplant, or destination therapy for end-stage cardiac patients who are ineligible for transplantation. Unlike conventional medical devices, cardiac assist systems require multidisciplinary implant teams, intensive postoperative monitoring, and long-term anticoagulation management, placing them at the intersection of advanced engineering and critical care medicine. According to sources, the number of people living with heart failure in the European Union is rising, driven by improved survival rates and an aging population, resulting in a growing, continuous need for mechanical circulatory support due to a shortage of available donor hearts. As per research, because the number of donor organs remains scarce, a significant, growing patient population is relying on mechanical, device-based solutions as a bridge to transplant or as long-term destination therapy. Furthermore, the aging population, more than one-fifth of EU citizens were aged sixty-five or older, as per Eurostat, exacerbates the prevalence of ischemic cardiomyopathy and valvular disease, the primary indications for assist device therapy. This confluence of unmet clinical need, demographic pressure, and technological evolution defines the high-stakes landscape of the European cardiac assist devices market.

MARKET DRIVERS

Rising Prevalence of Heart Failure and Limited Donor Organ Availability

The escalating burden of heart failure across the region is the foremost driver of the European cardiac assist device market. This is because pharmacological and surgical options have reached their limits for advanced cases. Heart failure prevalence in Europe is increasing, driven by longer life expectancy in the population and improved survival from heart attacks. Critically, the supply of donor hearts remains static. Eurotransplant faces a critical shortage of donor hearts, with annual transplant numbers falling far short of the total need. This gap forces clinicians to rely on mechanical circulatory support as a bridge to transplant or destination therapy. The number of ventricular assist devices implanted in Germany is rising, reflecting increasing utilization of mechanical support for advanced heart failure. Similarly, the UK National Health Service continues to expand and refine its ventricular assist device program to address the mortality risk for patients on the transplant waiting list. Studies in the European Heart Journal emphasized that in patients with advanced stage heart failure, long-term mechanical circulatory support offers a significant survival advantage over medical management. Rising diabetes and hypertension trends project a notable surge in heart failure by 2030, shifting mechanical support from a final option to a cornerstone of care.

Advancements in Minimally Invasive and Durable Device Technologies

Technological innovation is transforming cardiac assist devices from bulky, high-complication systems into smaller, more durable, and patient-friendly solutions, which further contributes to the expansion of the European cardiac assist devices market. This evolution is expanding candidacy beyond traditional transplant-eligible cohorts. According to the European Association for Cardio Thoracic Surgery, third-generation continuous flow left ventricular assist devices achieve two-year survival rates exceeding 70 percent, with infection and stroke rates reduced compared to first-generation pulsatile pumps. A key enabler is the shift toward magnetically levitated impellers that eliminate mechanical wear and reduce hemolysis, as seen in Abbott’s HeartMate 3, which received CE Mark in 2015 and is standard in numerous European centers. Additionally, percutaneous devices like Abiomed’s Impella CP offer temporary support via femoral artery access, enabling use in acute myocardial infarction or high-risk PCI without open chest surgery. The European Society of Cardiology guidelines and associated clinical consensus statements indicate a trend toward considering mechanical circulatory support earlier for appropriate ambulatory heart failure patients, rather than waiting for advanced, refractory decline. In Sweden, Karolinska University Hospital points out that, based on their experience with HeartMate 3, patients implanted with these newer, more hemocompatible devices experience improved quality-of-life metrics and enhanced functional capacity. Quieter, smaller, and home-compatible, these devices appeal to patients and clinicians focusing on functional restoration rather than just survival.

MARKET RESTRAINTS

Stringent Regulatory Pathways Under EU MDR Delaying Device Approvals

The implementation of the European Union Medical Devices Regulation has significantly extended approval timelines for novel cardiac assist devices, which restrains the growth of the European cardiac assist devices market. As a result, this has constrained innovation cycles and limited patient access to next-generation technologies. The transition to the European Medical Device Regulation has significantly increased the time required to secure CE marking compared to the previous directive, primarily driven by heightened demands for clinical evidence, enhanced post-market surveillance, and limited Notified Body capacity. Recent evaluations of European medical device submissions show that high-risk cardiovascular devices frequently face delays in certification, with insufficient long-term durability evidence and incomplete risk management documentation identified as primary, recurring issues. This barrier disproportionately affects small innovators. Surveys from European medical technology associations indicate that the challenging regulatory environment under the new MDR has caused a significant reduction in the launch of new, innovative medical devices, with startups and small enterprises particularly struggling to bring novel products to market. Consequently, many companies prioritize US FDA approval first, delaying European availability by several months. Slow capacity growth in notified bodies and evolving guidance on equivalence will continue to delay the adoption of life-saving innovations in Europe.

High Procedure Costs and Reimbursement Variability Across Member States

Inconsistent reimbursement policies and high upfront costs restrict widespread adoption of cardiac assist devices across the region’s fragmented healthcare systems, despite clinical benefits. This hampers the expansion of the European cardiac assist devices market. According to sources, while Germany and France provide comprehensive coverage for VAD implantation and follow-up, countries like Poland, Romania, and Greece offer partial or no reimbursement, forcing patients to seek treatment abroad or forego therapy. Regionalized health budget control contributes to extended wait times for specific, high-cost cardiac implant procedures. The total cost of ventricular assist device procedures imposes significant financial pressure on hospital budgets, which are already strained by accumulated care backlogs. Financial constraints are driving a trend to prioritize, or limit, access to advanced, high-cost cardiac technology for specific patient populations. Despite clinical guidelines, economic factors are increasing the reliance on alternative, less resource-intensive treatment strategies. Access to these life-sustaining devices will remain unequal across Europe until reimbursement models are harmonized to account for long-term savings in hospitalization and productivity.

MARKET OPPORTUNITIES

Expansion of Destination Therapy for End-Stage Heart Failure Patients

The growing acceptance of ventricular assist devices as destination therapy, rather than solely a bridge to transplant, is opening a substantial new patient population previously excluded from mechanical support, which is expected to boost the growth of the European cardiac assist devices market. The European Society of Cardiology (ESC) recognizes that a significant majority of advanced heart failure patients are ineligible for transplantation, with factors like advanced age, comorbidities, and psychosocial barriers restricting access to this treatment. Recent clinical evidence supports this shift. Recent data from the MOMENTUM 3 trial and related registries show that older patients receiving HeartMate 3 left ventricular assist devices (LVADs) experience survival outcomes and functional improvement levels similar to those of younger patients. National health systems are adapting. German statutory insurance coverage for destination therapy has increased access to LVAD technology for older patients, leading to a rise in implants among this demographic. Similarly, Swedish national guidelines are increasingly focusing on patient frailty and comprehensive assessment, rather than strict chronological age, to determine eligibility for ventricular assist devices (VADs). The advent of durable, user-friendly devices with ultra-light, home-discharge-enabled controllers has brought a dramatic, positive change in quality of life. This paradigm shift transforms VADs from temporary rescue tools into chronic disease management platforms, dramatically expanding the addressable market across Europe’s aging population.

Integration of Remote Monitoring and Digital Health Platforms

The incorporation of telemedicine and real-time device telemetry is enhancing post-implant care, reducing hospital readmissions, and enabling earlier intervention for complications, which paves the way for potential prospects for the European cardiac assist devices market. Many ventricular assist device centers in Western Europe have adopted remote systems that transmit daily performance data, such as pump speed and power consumption, to clinical teams. Technologies, including those from major medical device manufacturers, enable the identification of potential issues like arrhythmias or infections before patient symptoms appear. Research indicates that remote monitoring is associated with a decrease in both unplanned hospitalizations and emergency department visits for patients. Clinical programs are increasingly exploring the use of algorithms to anticipate potential adverse events in advance, which supports proactive adjustments in care. European initiatives are directing resources to support the infrastructure necessary for connected implantable devices, highlighting a focus on sustainable chronic care models. Procurement strategies are prioritizing remote-enabled, connected technology, driving the market for next-generation, data-analytic health systems.

MARKET CHALLENGES

Shortage of Specialized Implant Centers and Trained Personnel

The concentration of cardiac assist expertise in a limited number of high-volume centers creates significant access barriers for patients in rural or Eastern European regions and for the European cardiac assist devices market. VAD implantation in the European Union is heavily concentrated in a limited number of specialized centers, with a significant majority of these procedures performed in Germany, France, Italy, and the UK. In countries like Bulgaria, Romania, and Slovakia, no certified VAD programs exist, forcing patients to travel abroad at personal expense. Even where centers exist, staffing shortages impede scale. There is a recognized shortage of certified perfusionists and VAD coordinators across Europe, impacting the capacity for advanced mechanical circulatory support. A significant portion of potential VAD candidates in Germany are denied implants due to limited ICU capacity and a shortage of specialized nursing staff. Training is highly specialized, ed requiring numerous months of fellowship beyond cardiac surgery, limiting workforce expansion. The life-saving potential of cardiac assist devices will not be fully realized across Europe without coordinated investment in specialized training, mobile teams, and standardized care.

Long-Term Anticoagulation Risks and Bleeding Complications

The necessity of lifelong anticoagulation therapy with cardiac assist devices poses a persistent clinical challenge that limits candidacy, increases morbidity, and hinders the expansion of tEuropeanope cardiac assist devices market. According to sources, major bleeding events occur in a portion of VAD patients annually, with gastrointestinal angiodysplasia being the most common cause due to shear stress induced von Willebrand factor degradation. Stroke remains a leading cause of death. These risks exclude patients with prior bleeding disorders, history of stroke,e or those unable to adhere to strict INR monitoring, groups that constitute a portion of advanced heart failure patients as per sources. Anticoagulation remains essential despite the lower thrombosis rates seen with the HeartMate 3, forcing clinicians to manage the dangerous bleeding risks associated with the treatment itself. Research into surface modifications and biocompatible coatings aims to mitigate this, but no commercial device yet eliminates the need.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The Ventricular Assist Devices (VADs) segment held the majority share of the European cardiac assist devices market in 2025. The prominence of the VADs segment is attributed to its versatility in supporting both left and right ventricular failure across a spectrum of indications, including bridge to transplant,t destination therapy, py and bridge to recovery. Also pushing this segment is the rising prevalence end-stageage heart failure. A large number of people in Europe live with heart failure, and the number of heart transplants performed is considerably lower than the number of people who could benefit from them. VADs fill this gap effectively. Newer generations of heart assist devices have shown promising results in supporting patients with advanced heart failure over several years. National health systems reinforce adoption. Access to advanced medical devices varies by region, with some areas having more specialized centers and coverage policies than others. Additionally, technological advances have reduced complications, and magnetically levitated impellers minimize hemolysis and stroke risk, enabling broader use beyond traditional transplant candidates. "VADs remain a cornerstone of European mechanical circulatory support, particularly as heart failure prevalence is projected to rise by 2030 due to aging and comorbidities."

The Total Artificial Hearts (TAHs) segment is on the rise and is expected to be the fastest-growing segment in the market by witnessing a CAGR of 9.3% between 2026 and 2034 due to increasing recognition of biventricular failure as a distinct clinical entity requiring complete cardiac replacement rather than partial support. Historically limited to experimental use, TAHs are gaining traction with the CE Mark approval of next-generation devices like the BiVACOR and Carmat Aeson, which offer improved biocompatibility and longer durability. An additive driver is the growing number of heart failure patients with right ventricular dysfunction who fail VAD therapy. Registry data indicate a growing proportion of patients with advanced heart failure are presenting with biventricular involvement, suggesting a shift toward more complex disease profiles requiring mechanical support. In the French market, a specific artificial heart device has achieved national reimbursement status, marking a shift toward greater adoption following clinical evaluations that showed favorable outcomes. Additionally, destination therapy protocols are being updated to include TAHs for patients ineligible for transplant due to size or anatomy. Advancements in surgical techniques and device reliability are transforming TAHs from a last-resort measure into a viable therapeutic option for complex biventricular failure in specialized European centers.

By End User Insights

The hospitals segment was the largest segment in the European cardiac assist devices market by capturing a significant share in 2025. The supremacy of the hospitals segment is credited to the highly complex nature of cardiac assist procedures, which require specialized operating rooms, intensive care units perfusionis, ts cardiac surgeons, and long-term multidisciplinary follow-up teams. Only certified tertiary hospitals possess the infrastructure and staffing to manage these high acuity interventions. Mechanical circulatory support procedures, such as VAD or TAH implantations, are concentrated within a limited number of specialized cardiac centers across Europe. In Germany, the performance of VAD procedures is restricted to university-affiliated cardiac centers that maintain specialized, dedicated programs for mechanical circulatory support. Regulatory frameworks further concentrate activity. National health authorities in France, Italy,y and the UK mandate that only accredited centers can implant Class III circulatory devices. Even temporary support like IABP insertion typically occurs in hospital catheterization labs during acute myocardial infarction management. Given the life-critical nature of these technologies and the absence of outpatient capability for major implantation, hospitals will remain the exclusive end user for the foreseeable future.

The Ambulatory Surgical Centers (ASCs) segment is predicted to witness the highest CAGR of 7.1% during the forecast period, owing to post discharge follow up care, including driveline dressing change,s anticoagulation monitoring, and device troubleshooting. The trend of discharging VAD patients earlier has moved routine maintenance from hospitals to local ASCs, which eases the burden on acute care centers. Partnerships between specialized academic centers and regional care facilities are being utilized to manage patients with ventricular assist devices through remote data monitoring. This collaborative approach allows for tailored in-person follow-ups based on the information gathered remotely, while regional care models appear to reduce patient readmissions and lessen the need for travel. Regulatory evolution supports this trend. ASCs are rapidly becoming central to community-based VAD management as systems prioritize dehospitalization, even though they will not perform the initial implants.

By Application Insights

The Bridge to Transplant (BTT) segment remained dominant in theEuropeane cardiac assist devices market by accounting for a 52.3% share in 2025. The dominance of the BTT segment is driven by the continued reliance on transplantation as the gold standard for end-stage heart failure, with mechanical support serving as a life-sustaining interim solution. A further key driver is the persistent gap between donor organ availability and patient demand. The number of heart transplants performed within the Eurotransplant network remains low relative to the high volume of new heart failure diagnoses. Ventricular Assist Devices (VADs) serve as a crucial bridge for patients, allowing them to maintain or improve their functional status while waiting for a transplant. Advancements in technology, specifically the use of continuous flow VADs, have significantly increased the likelihood of patients remaining eligible for transplant compared to previous device generations. National transplant networks reinforce this model. In Europe, BTT remains the leading, most clinically validated use of cardiac assist devices, addressing the rising prevalence of heart failure amid limited donor organ supply.

The Destination Therapy (DT) segment is anticipated to witness the fastest CAGR of 10.6% between 2026 and 2034. The rapid expansion of the DT segment is propelled by the recognition that over 70 percent of advanced heart failure patients are permanently ineligible for transplantation due to age comorbidities or psychosocial factors, yet can benefit from long-term mechanical support. Recent clinical evidence validates this shift. Clinical data indicate that advanced, modern left ventricular assist devices provide improved survival and enhanced quality of life for elderly patients, including those over seventy. The expansion of coverage guidelines by insurers in certain European countries is increasing access to destination therapy for older patients. Regional healthcare systems are increasingly adopting standardized, frailty-based assessments to determine eligibility for ventricular support devices, allowing for the inclusion of older patients. There is a visible upward trend in the adoption of destination therapy, driven by the alignment of regional health authorities with international clinical recommendations. DT is no longer just an exception; reduced device size and weight have made it the standard of care for most heart failure patients not receiving a transplant.

COUNTRY LEVEL ANALYSIS

Germany Cardiac Assist Devices Market Analysis

Germany led the EEuropeancardiac assist devices market by holding a 28.4% share in 2025. The dominance of the German market is attributed to a high volume of certified implant centers, robust public reimbursement, and strong research infrastructure. The country also hosts Europe’s most comprehensive mechanical circulatory support registry, enabling real-time outcome tracking and protocol refinement. Regulatory rigor ensures quality; the Federal Joint Committee mandates annual center certification based on volume and survival metrics. Additionally, Germany leads in innovation with participation in global trials for next-generation devices like the BiVACOR total artificial heart. Germany sets the benchmark for European mechanical circulatory support, leveraging a robust, centralized cardiac care network to manage an aging population.

France Cardiac Assist Devices Market Analysis

France was the next prominent country in the European cardiac assist devices market by occupying a 19.7% share in 2025. The growth of the French market is fuelled by its pioneering role in total artificial heart development and strong public health integration. Total artificial heart technology in France remains under active clinical investigation through specialized early access programs, rather than having achieved full, established national reimbursement. Strategic steps are currently in progress to transition these devices from clinical study funding toward standard national insurance coverage. Advanced biventricular support is provided through a network of specialized medical centers that integrate clinical innovation into regional healthcare pathways. The utilization of these complex therapies is governed by national regulatory frameworks to ensure procedural safety and consistent patient care. A clear pattern of increasing adoption exists for various cardiac assist technologies as clinical evidence matures and medical teams become more proficient. The French Health Authority mandates multidisciplinary team reviews for all implants, ensuring appropriate patient selection. Additionally, France benefits fromcross-borderr collaboration with Belgium and Switzerland for organ sharing, reducing waitlist mortality. France maintains a high influence-to-volume ratio in the European cardiac assist sector, driven by consistent funding for bioengineered hearts and universal access to care.

United Kingdom Cardiac Assist Devices Market Analysis

The United Kingdom maintains a significant position in the European cardiac assist devices market. Despite Brexit, the NHS maintains strong procedural volume through its centralized VAD program spanning several specialized centers. The utilization of mechanical circulatory support devices shows an upward trend, with efforts focused on mitigating regional inequalities in patient access. Strategic initiatives within national healthcare planning are investing in capacity expansion and training specialized staff to support the growing reliance on these technologies. Remote monitoring technology is widespread among patients with ventricular assist devices, which is associated with a reduction in unplanned hospital admissions. Procurement strategies within the healthcare system are exerting downward pressure on device pricing, which tends to benefit established manufacturers and impact market dynamics. The UK manages to balance, through academic-driven research and digital adoption, ambitious technological progress with a sound financial framework.

Italy Cardiac Assist Devices Market Analysis

Italy experienced a consistent expansion in the European cardiac assist devices market owing to regional variation. Northern centers, like San Donato in Milan, perform high volume,s while Southern regions face access gaps. The utilization of ventricular assist devices has increased, with a notable rise in their application for long-term management, influenced by updated regional funding guidelines that align with broader European clinical recommendations. The national landscape in this field is characterized by high levels of surgical experience, resulting in some of the lowest reported perioperative mortality rates across the continent. The National Transplant Center coordinates organ allocation efficiently, but donor rates remain below Northern European averages. Private clinics also contribute, offering faster access for self-pay patients. Despite financial constraints in certain areas, Italy’s healthcare system continues to advance, driven by strong clinical outcomes and gradual policy alignment.

Sweden Cardiac Assist Devices Market Analysis

Sweden is predicted to grow in the European cardiac assist devices market over the forecast period. Despite its modest population, Sweden exerts disproportionate influence through early adoption of destination therapy and digital health integration. Policies regarding eligibility for ventricular assist devices have transitioned away from strictly enforced chronological age restrictions, moving toward individualized evaluations based on functional status and co-existing conditions, a trend observed in several Northern European nations. Healthcare facilities in Sweden have experienced a rise in the adoption of durable mechanical circulatory support, supported by accelerated recovery protocols and remote monitoring systems. The integration of predictive, data-driven modeling into cardiovascular care is expanding, with research centers utilizing algorithms to proactively identify potential patient complications. Universal healthcare ensures equitable access, and wait times for evaluation average just three weeks. Sweden acts as a premier European model for sustainable mechanical circulatory support, driven by a patient-centric design, transparent data sharing, and a strong culture of innovation. This approach ensures high-value care and sets a standard for the region.

TOP LEADING PLAYERS IN THE MARKET

• Abbott is a global leader in mechanical circulatory support with its HeartMate 3 left ventricular assist device serving as the standard of care across Europe for both bridge to transplant and destination therapy. The company supplies advanced continuous flow VADs to over ninety certified centers in Germany, France, the UK, and Scandinavia, supported by comprehensive training programs and 24 7 clinical support. It also partnered with national heart registries to integrate real-world outcome data into device optimization. These initiatives reinforce Abbott’s role as an enabler of sustainable long-term VAD therapy, not only in Europe but globally,y where its technology sets benchmarks for survival and quality of life.
• Medtronic plays a pivotal role in thEuropeanpe cardiac assist devices market through its HVAD system and temporary support platforms, including the Impella percutaneous heart pumps. The company focuses on acute andsub-acutee settings, offering solutions for high-risk PCI cardiogenic shock and post-cardiotomy support across over one hundred hospitals in Italy, Spain, and the Netherlands. It also expanded its Heart Recovery Program in Eastern Europe,e training multidisciplinary teams in bridge to recovery protocols. Medtronic strengthens its position as a global leader in full-spectrum mechanical circulatory care by offering a combined portfolio of temporary and durable support options.
• Carmat is France-baseded innovator specializing in total artificial heart technology, with its Aeson TAH representing Europe’s most advanced biventricular replacement solution. It also enhanced biocompatibility through a novel micro-porous membrane that reduces anticoagulation needs. Carmat’s position as Europe's only developer of an implantable TAH provides a vital sovereign advantage to the region’s cardiac care network and establishes a new global standard for biohybrid technology.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in theEuropeane Cardiac Assist Devices Market invest heavily in remote monitoring and digital health platforms to enable early complication detection and reduce hospital readmissions. They establish comprehensive training academies and certification programs for implant centers to ensure procedural excellence and patient safety. Companies forge strategic partnerships with national heart registries to generate real-world evidence on long-term outcomes and support reimbursement decisions. They develop next-generation devices with improved hemocompatibility, reduced size, and lower anticoagulation requirements to expand patient eligibility. Additionally, ly they expand access through multicenter clinical rollouts across-border collaborations to address geographic disparities in specialized care.

COMPETITIVE LANDSCAPE

Competition in the European Cardiac Assist Devices Market is highly specialized and technologically intense, characterized by a triad of global leaders competing on clinical outcome, durability, ty and digital integration rather than price. The market is dominated by Class III implantable devices requiring extensive regulatory validation under the EU Medical DeviceRegulationat, which creates high barriers to entry. Incumbents differentiate through survival data quality of life metrics and service infrastructure, including 24 7 technical support and training programs. National heart registries like EUROMACS exert significant influence by publicly reporting center and device performance,e thereby steering clinical preference toward proven platforms. While VADs dominatevolumeutheee TAHs representhigh-valuelue niche where innovation is accelerating. Reimbursement fragmentation remains a challenge, with Western European countries offering comprehensive coverage while Eastern nations lag significantly. Competition is increasingly focused on lifetime value, balancing upfront cost against readmission rate,s functional recovery,ry and caregiver burden as European healthcare systems prioritize sustainable chronic disease management for an aging population with advanced heart failure.

KEY MARKET PLAYERS

The top companies in the European Cardiac Assist Devices Market are

• Thoratec Corporation
• MAQUET GmbH & Co
• Teleflex Incorporated
• Berlin Heart GmbH
• Abiomed, Inc.
• HeartWare International
• SynCardia Systems, Inc.
• Jarvik Heart, Inc.
• Terumo Corporation
• Braile Biomedica Ltd.
• CardiacAssist, Inc.
• CardioBridge GmbH
• Carmat SAS
• Cleveland Heart, Inc.
• CorAssist Cardiovascular Ltd.
• Evaheart Medical USA, Inc.
• Leviticus Cardio Ltd.
• MyoCardioCare, Inc.

MARKET SEGMENTATION

This research report on the europe cardiac assist devices market has been segmented and sub-segmented into the following categories.

By Product Type

• Ventricular Assist Devices (VADs)
  • Left Ventricular Assist Devices (LVADs)
  • Right Ventricular Assist Devices (RVADs)
  • Biventricular Assist Devices (BiVADs)
  • External Ventricular Assist Devices
• Intra-Aortic Balloon Pumps (IABPs)
• Total Artificial Hearts (TAHs)

By Modality

• Implantable Devices
• Transcutaneous Devices

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)

By Flow Type

• Pulsatile Flow Devices
• Continuous Flow Devices

By Application

• Bridge to Transplant (BTT)
• Destination Therapy (DT)
• Bridge to Recovery (BTR)
• Bridge to Candidacy (BTC)

By Country

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerlandd
• Netherlands and the rest of Europe